TD Cowen cut shares of Galapagos (NASDAQ:GLPG – Free Report) from a strong-buy rating to a strong sell rating in a report released on Thursday,Zacks.com reports. Other equities analysts also recently ...

U.S.-listed shares rose over 4% in Wednesday's premarket after it announced a significant restructuring plan, including a ...

Leerink Partners analyst Faisal Khurshid has maintained their neutral stance on GLPG stock, giving a Hold rating on December 23.Stay Ahead of ...

Belgian biotech Galapagos (NASDAQ:GLPG) announced a major restructuring drive on Wednesday, with plans to amend its 10-year ...

Galapagos (GLPG) will focus on unlocking the potential of its decentralized cell therapy manufacturing platform in oncology and will continue ...

Galapagos NV plans to split into two entities by mid-2025, focusing on oncology cell therapy and innovative medicines, with ...

Galapagos plans to split into two entities by mid-2025, focusing its core business on cell therapies while spinning off a new ...

Galapagos intends to create a new company with approximately €2.45 billion in cash dedicated to building a pipeline of innovative medicines through transformational transactions Galapagos will gain ...

Given GLPG's returns in the past year, this is a prime example of the difficulty in investing in a biotechnology stock just because it's trading near or below cash. Remember that stock valuations ...